You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Related products

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »
 

Anti-PARK7/DJ1 antibody (ab4150)

CodeSizePriceAbpointsAvailability
    
 
  • -
  •   
  •   
  •   
  •  
  •   
  •   
Updating...

Overview

Product name

Anti-PARK7/DJ1 antibody
See all PARK7/DJ1 products (15) ...

Description

Goat polyclonal to PARK7/DJ1

Tested applications

IP, WBmore details

Cross reactivity

Reacts with

Mouse, Human

Predicted to work with

Rat

Immunogen

Synthetic peptide: C-AAQVKAPLVLKD, corresponding to C terminal amino acids 178-189 of Human PARK7/DJ1 (Peptide available as ab22993.)

C-AAQVKAPL VLKD

Positive control

WB: Jurkat lysate, HeLa whole cell lysate , 3T3 whole cell lysate

Properties

Form

Liquid

Storage instructions

Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

Storage buffer

Preservative: 0.02% Sodium Azide
Constituents: 0.5% BSA, 5mg/ml Tris, pH 7.3

Concentration

Concentration information loading...

Purity

IgG fraction

Purification notes

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Clonality

Polyclonal

Isotype

IgG

  • Western blot - PARK7/DJ1 antibody (ab4150)Western blot - PARK7/DJ1 antibody (ab4150) image (enlarge)

  • Western blot - PARK7/DJ1 antibody (ab4150)Western blot - PARK7/DJ1 antibody (ab4150) image (enlarge)

  • Western blot - PARK7/DJ1 antibody (ab4150)Western blot - PARK7/DJ1 antibody (ab4150) image (enlarge)

Applications

Show applications key

Our Abpromise guarantee covers the use of ab4150 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Target

Function

Protects cells against oxidative stress and cell death. Plays a role in regulating expression or stability of the mitochondrial uncoupling proteins SLC25A14 and SLC25A27 in dopaminergic neurons of the substantia nigra pars compacta and attenuates the oxidative stress induced by calcium entry into the neurons via L-type channels during pacemaking. Eliminates hydrogen peroxide and protects cells against hydrogen peroxide-induced cell death. May act as an atypical peroxiredoxin-like peroxidase that scavenges hydrogen peroxide. Following removal of a C-terminal peptide, displays protease activity and enhanced cytoprotective action against oxidative stress-induced apoptosis. Stabilizes NFE2L2 by preventing its association with KEAP1 and its subsequent ubiquitination. Binds to OTUD7B and inhibits its deubiquitinating activity. Enhances RELA nuclear translocation. Binds to a number of mRNAs containing multiple copies of GG or CC motifs and partially inhibits their translation but dissociates following oxidative stress. Required for correct mitochondrial morphology and function and for autophagy of dysfunctional mitochondria. Regulates astrocyte inflammatory responses. Acts as a positive regulator of androgen receptor-dependent transcription. Prevents aggregation of SNCA. Plays a role in fertilization. Has no proteolytic activity. Has cell-growth promoting activity and transforming activity. May function as a redox-sensitive chaperone.

Tissue specificity

Highly expressed in pancreas, kidney, skeletal muscle, liver, testis and heart. Detected at slightly lower levels in placenta and brain. Detected in astrocytes, Sertoli cells, spermatogonia, spermatids and spermatozoa.

Involvement in disease

Defects in PARK7 are the cause of Parkinson disease type 7 (PARK7) [MIM:606324]. A neurodegenerative disorder characterized by resting tremor, postural tremor, bradykinesia, muscular rigidity, anxiety and psychotic episodes. PARK7 has onset before 40 years, slow progression and initial good response to levodopa. Some patients may show traits reminiscent of amyotrophic lateral sclerosis-parkinsonism/dementia complex (Guam disease).

Sequence similarities

Belongs to the peptidase C56 family.

Post-translational
modifications

Sumoylated on Lys-130 by PIAS2 or PIAS4; which is enhanced after ultraviolet irradiation and essential for cell-growth promoting activity and transforming activity.
Cys-106 is easily oxidized to sulfinic acid.
Undergoes cleavage of a C-terminal peptide and subsequent activation of protease activity in response to oxidative stress.

Cellular localization

Cytoplasm. Nucleus. Mitochondrion. Under normal conditions, located predominantly in the cytoplasm and, to a lesser extent, in the nucleus and mitochondrion. Translocates to the mitochondrion and subsequently to the nucleus in response to oxidative stress and exerts an increased cytoprotective effect against oxidative damage. Detected in tau inclusions in brains from neurodegenerative disease patients.

Target information above from: UniProt accessionQ99497 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • CAP1 antibody
  • DJ 1 antibody
  • DJ-1 antibody
  • DJ1 antibody
  • DJ1 protein antibody
  • DJ1 protein antibody
  • FLJ27376 antibody
  • FLJ34360 antibody
  • FLJ92274 antibody
  • Oncogene DJ1 antibody
  • OTTHUMP00000001348 antibody
  • OTTHUMP00000001349 antibody
  • OTTHUMP00000001350 antibody
  • OTTHUMP00000001351 antibody
  • Park 7 antibody
  • Park7 antibody
  • PARK7_HUMAN antibody
  • Parkinson disease (autosomal recessive early onset) 7 antibody
  • Parkinson disease (autosomal recessive, early onset) 7 antibody
  • Parkinson disease protein 7 antibody
  • Protein DJ 1 antibody
  • Protein DJ-1 antibody
  • RNA binding protein regulatory subunit antibody
  • RS antibody
  • SP22 antibody
see all

Anti-PARK7/DJ1 antibody images:

  Western blot - PARK7/DJ1 antibody (ab4150)

Western blot - PARK7/DJ1 antibody (ab4150)



Predicted band size : 20 kDa


ab4150 staining (1µg/ml) of Jurkat lysate (RIPA buffer, 30µg total protein per lane). Primary incubated for 1 hour. Detected by western blot using chemiluminescence.

  Western blot - PARK7/DJ1 antibody (ab4150)

Western blot - PARK7/DJ1 antibody (ab4150)



Predicted band size : 20 kDa


Western blot using ab4150 at 1/500.
Exposure time: 30s.

Left hand lane: HeLa whole cell lysate (human)
Right hand lane: 3T3 whole cell lysate (mouse)

  Western blot - PARK7/DJ1 antibody (ab4150)

Western blot - PARK7/DJ1 antibody (ab4150)

Anti-PARK7/DJ1 antibody (ab4150) at 1/6000 dilution

Secondary
HRP conjugated Donkey anti mouse at 1/10000 dilution
developed using the ECL technique

Performed under reducing conditions.

Predicted band size : 20 kDa
Observed band size : 24 kDa (why is the actual band size different from the predicted?)


Exposure time : 1 minute

This image is courtesy of an anonymous Abreview

See Abreview

References for Anti-PARK7/DJ1 antibody (ab4150)

This product has been referenced in:

  • Miyama Aet al. Oxidation of DJ-1 Induced by 6-Hydroxydopamine Decreasing Intracellular Glutathione. PLoS One 6:e27883 (2011). WB; Human.Read more (PubMed: 22132160) »
  • Aron Let al. Pro-survival role for Parkinson's associated gene DJ-1 revealed in trophically impaired dopaminergic neurons. PLoS Biol 8:e1000349 (2010). WB; Mouse.Read more (PubMed: 20386724) »

See all 7 publications for this product

Publishing research using ab4150? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"